MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.451
+0.011
+0.74%
Opening 15:02 01/20 EST
OPEN
1.480
PREV CLOSE
1.440
HIGH
1.505
LOW
1.441
VOLUME
151.01K
TURNOVER
--
52 WEEK HIGH
20.00
52 WEEK LOW
1.400
MARKET CAP
57.17M
P/E (TTM)
-4.5334
1D
5D
1M
3M
1Y
5Y
Second Sight Medical US Patent & Trademark Office Abstract For Co.'s 'Method and apparatus to provide safety checks for neural stimulation'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11173305.PN.&OS=PN/11173305&RS=PN/11173305
Benzinga · 11/16/2021 18:41
MAT, ENDP and PALI among pre market gainers
Phunware (NASDAQ:PHUN) +286%. Digital World Acquisition (NASDAQ:DWAC) +94%. Creatd (NASDAQ:CRTD) +56% debuts Camp's website redesign and new product launches Yunhong CTI (NASDAQ:CTIB) +14%. Xiaobai Maimai (NASDAQ:HX) +15%. Salem Media Group (NASDAQ:SALM) +...
Seekingalpha · 10/22/2021 12:33
Second Sight Medical Products US Patent & Trademark Office Abstract For Co.'s 'Method and apparatus to provide safety checks for neural stimulation'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11129984.PN.&OS=PN/11129984&RS=PN/11129984
Benzinga · 09/28/2021 13:54
Avoid These 3 Stocks
StockNews.com · 08/24/2021 09:31
Second Sight Obtains New NIH Grant Supplement for Visual Neuroprostheses Study
MT Newswires · 08/11/2021 07:00
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 07/23/2021 20:50
CLOV Stock: What Reddit Investors Are Saying About Clover Health Today as Shares Climb
Investor Place · 07/22/2021 15:31
MRIN Stock: 10 Things for Marin Software Investors to Know About the Popular Meme Stock Today
Investor Place · 07/22/2021 14:53
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYES. Analyze the recent business situations of Second Sight Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EYES stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
High2.500
Average2.500
Low2.500
Current 1.455
EPS
Actual
Estimate
-0.34-0.26-0.17-0.09
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 68
Institutional Holdings: 3.77M
% Owned: 9.56%
Shares Outstanding: 39.41M
TypeInstitutionsShares
Increased
9
370.61K
New
10
297.43K
Decreased
11
986.71K
Sold Out
16
736.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.22%
Healthcare Equipment & Supplies
+1.03%
Key Executives
Chairman/Director
Gregg Williams
Chief Executive Officer
Scott Dunbar
Vice President - Operations
Edward Randolph
Other
Stephen Okland
Director
Alexandra Larson
Director
Jonathan McGuire
Independent Director
Dean Baker
Independent Director
Aaron Mendelsohn
Independent Director
Matthew Pfeffer
No Data
About EYES
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYES real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYES stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYES stock methods without spending real money on the virtual paper trading platform.